The online retailer will be able to provide customers with a selection of migraine, obesity, and diabetes medications.
You really can get almost anything from Amazon.
The online retail giant announced that it has entered into a partnership with Eli Lilly to distribute certain medications through Amazon Pharmacy. According to a press release, the deal will allow customers to get these medications delivered directly to their homes.1 Amazon customers will be able to access these drugs alongside Amazon Pharmacy’s full suite of pharmacy support.
The partnership will provide the medications through LillyDirect, a digital end-to-end healthcare provider that provides patients with access to telehealth options and prescriptions for obesity, migraine, and diabetes treatments. Amazon is the second online pharmacy to partner with Eli Lilly’s digital platform, and the online retailer will serve as a third-part dispensing provider.
Amazon Pharmacy offers customers access to clinical pharmacists while also monitoring incoming prescriptions. The platform’s pharmacists can notify customers of important details about their prescriptions, such as potential drug interactions.
As is the case with the majority of Amazon deliveries, customers ordering their prescriptions through Amazon Pharmacy will have the ability to track their deliveries in near real time and receive delivery notifications.
Customers will also have access to pharmacists for medication management support. According to Amazon, customers who find themselves having to use an injectable medication for the first time will be able to contact these pharmacists for support. They’ll be able to set up virtual meetings in order to ensure that they are administering the medication correctly.
This partnership is a part of two growing trends. First, weight-loss drugs are seeing a rise in prominence in the US. Consumers are moving away from fad diets and personal trainers and are seeking medical intervention for obesity and obesity related issues at higher numbers than before. This has caused a strain on the supply chain, and popular drugs like Wegovy have been difficult to find for many hopeful users. Novo Nordisk, the drug’s developer, has taken steps to increase the supply of the drug in recent months, such as acquiring Catalent and bringing multiple production sites under their umbrella.
Secondly, there is a growing rise in direct-to-consumer pharmaceuticals platforms. Several drug developers are building their own platforms so that patients will be able to fulfill their prescriptions directly from the drug supplier, as opposed to having to go to a pharmacy. LillyDirect partnering with Amazon Pharmacy gives the platform access to the retailer’s massive network of warehouses, storage sites, and delivering fleets. According to the companies, the goal is to provide patients with more convenient and less expensive ways of obtaining the medications that they require.
Amazon Pharmacy accepts a wide variety of insurance plans, and offers discount programs through PrimeRx and RxPass. Patients obtaining their medications through Amazon Pharmacy can direct their prescriptions to either Amazon Pharmacy or LillyDirect.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.